|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0120 AUD | +4.35% |
|
+4.35% | -20.00% |
| 28/05 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 27/05 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.3M 3.76M 3.47M 3.2M 6.03M 414M 41.45M 16.3M 203M 16.15M 15.8M 698M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.24M 5.45M 5.03M 4.64M 8.74M 601M 60.11M 23.64M 294M 23.42M 22.91M 1.01B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +4.35% | ||
| 1 week | +4.35% | ||
| 1 month | -20.00% | ||
| 3 months | +9.09% | ||
| 6 months | -17.24% | ||
| Current year | -20.00% |
| 1 week | 0.01 | 0.01 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.35% | +4.35% | -25.00% | -76.00% | 4.3M | ||
| -0.90% | -0.15% | +13.46% | +79.34% | 48.15B | ||
| -0.23% | -1.65% | +65.14% | +115.81% | 35.59B | ||
| -0.76% | -1.44% | -4.30% | +37.38% | 11.9B | ||
| -0.88% | -0.62% | +16.38% | +89.65% | 11.85B | ||
| +0.19% | +2.87% | +34.92% | +127.54% | 9.31B | ||
| -0.75% | -0.91% | +18.26% | +37.23% | 6.91B | ||
| -9.93% | +0.35% | -29.90% | +14.89% | 6.13B | ||
| +3.37% | -0.10% | +49.31% | -4.38% | 7.02B | ||
| -2.25% | -2.08% | +0.40% | +218.27% | 6.55B | ||
| Average | -0.78% | +0.49% | +13.87% | +63.97% | 14.34B | |
| Weighted average by Cap. | -0.88% | -0.42% | +25.98% | +86.35% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.55M 3.11M 2.87M 2.64M 4.98M 342M 34.26M 13.48M 168M 13.35M 13.06M 577M | 1.19M 831K 726K 670K 618K 1.16M 80.02M 8.01M 3.15M 39.19M 3.12M 3.05M 135M |
| Net income | -5.8M -4.05M -3.54M -3.27M -3.01M -5.67M -390M -39.04M -15.35M -191M -15.21M -14.88M -658M | -5.94M -4.15M -3.63M -3.35M -3.09M -5.82M -400M -40.01M -15.74M -196M -15.59M -15.25M -674M |
| Net Debt | 759K 530K 463K 427K 394K 743K 51.04M 5.11M 2.01M 25M 1.99M 1.95M 86.05M | 2.77M 1.94M 1.69M 1.56M 1.44M 2.71M 186M 18.66M 7.34M 91.29M 7.27M 7.11M 314M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | $0.0120 | +4.35% | 423,652 |
| 14/07/26 | $0.0115 | +4.55% | 2,185 |
| 13/07/26 | $0.0110 | -4.35% | 2,188 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















